Intravitreal Adalimumab in Active Noninfectious Uveitis: A Pilot Study

References

• Caspi R. Autoimmunity in the immune privileged eye: pathogenic and regulatory T cells. Immunol Res. 2008;42:41–50
   PubMed Web of Science ®Google Scholar
• Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol. 1996;80:844–848
   PubMed Web of Science ®Google Scholar
• Galor A, Jabs DA, Leder HA, et al. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology. 2008;115:1826–1832
   PubMed Web of Science ®Google Scholar
• Pujari SS, Kempen JH, Newcomb CW, et al. Cyclophosphamide for ocular inflammatory diseases. Ophthalmology. 2010;117:356–365
   PubMed Web of Science ®Google Scholar
• Murray PI, Sivaraj RR. Anti-TNF-alpha therapy for uveitis: Behçet and beyond. Eye (Lond). 2005;19:831–833
   PubMed Web of Science ®Google Scholar
• Robertson M, Liversidge J, Forrester JV, et al. Neutralizing tumor necrosis factor-alpha activity suppresses activation of infiltrating macrophages in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci. 2003;44:3034–3041
   PubMed Web of Science ®Google Scholar
• Santos Lacomba M, Marcos Martin C, Gallardo Galera JM, et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res. 2001;33:251–255
   PubMed Web of Science ®Google Scholar
• Perez-Guijo V, Santos-Lacomba M, Sanchez-Hernandez M, et al. Tumour necrosis factor-alpha levels in aqueous humour and serum from patients with uveitis: the involvement of HLA-B27. Curr Med Res Opin. 2004;20:155–157
   PubMed Web of Science ®Google Scholar
• Sugita S, Takase H, Taguchi C, Mochizuki M. The role of soluble TNF receptors for TNF-alpha in uveitis. Invest Ophthalmol Vis Sci. 2007;48:3246–3252
   PubMed Web of Science ®Google Scholar
• Imrie FR, Dick AD. Biologics in the treatment of uveitis. Curr Opin Ophthalmol. 2007;18:481–486
   PubMed Web of Science ®Google Scholar
• Lim L, Suhler EB, Smith JR. Biologic therapies for inflammatory eye disease. Clin Experiment Ophthalmol. 2006;34:365–374
   PubMed Web of Science ®Google Scholar
• Sobrin L, Kim EC, Christen W, et al. Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol. 2007;125:895–900
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease. Arthritis Rheum. 2005;52:2478–2484
   PubMed Web of Science ®Google Scholar
• Dobner BC, Max R, Becker MD, et al. A three-centre experience with adalimumab for the treatment of non-infectious uveitis. Br J Ophthalmol. 2013;97:134–138
   PubMed Web of Science ®Google Scholar
• Diaz-Llopis M, Garcia-Delpech S, Salom D, et al. Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther. 2008;24:351–361
   PubMed Web of Science ®Google Scholar
• Díaz-Llopis M, Salom D, Garcia-de-Vicuña C, et al. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology. 2012;119:1575–1581
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140:509–516
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Herbort CP, Khairallah M. Angiography Scoring for Uveitis Working Group (ASUWOG). Scoring of dual fluorescein and ICG inflammatory angiographic signs for the grading of posterior segment inflammation (dual fluorescein and ICG angiographic scoring system for uveitis). Int Ophthalmol. 2010;30:539–552
   PubMedGoogle Scholar
• Deuter CM, Kötter I, Wallace GR, et al. Behçet's disease: ocular effects and treatment. Prog Retin Eye Res. 2008;27:111–136
   PubMed Web of Science ®Google Scholar
• Lowder C, Belfort R Jr, Lightman S, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011;129:545–553
   PubMed Web of Science ®Google Scholar
• Wu L, Hernandez-Bogantes E, Roca JA, et al. Intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: a pilot study from the Pan-American Collaborative Retina Study Group. Retina. 2011;31:298–303
   PubMed Web of Science ®Google Scholar
• Manzano RP, Peyman GA, Carvounis PE, et al. Ocular toxicity of intravitreous adalimumab (Humira) in the rabbit. Graefes Arch Clin Exp Ophthalmol. 2008;246:907–911
   PubMed Web of Science ®Google Scholar
• Tsilimbaris M, Diakonis VF, Naoumidi I, et al. Evaluation of potential retinal toxicity of adalimumab (Humira). Graefes Arch Clin Exp Ophthalmol. 2009;247:1119–1125
   PubMed Web of Science ®Google Scholar
• Androudi S, Tsironi E, Kalageropoulos C, et al. Intravitreal adalimumab for refractory uveitis-related macular edema. Ophthalmology. 2010;117:1612–1616
   PubMed Web of Science ®Google Scholar